Reversal of extrahepatic membrane cholesterol deposition in patients with chronic liver diseases by S-adenosyl-l-methionine

1992 ◽  
Vol 83 (3) ◽  
pp. 353-356 ◽  
Author(s):  
Samina Rafique ◽  
Marianna Guardascione ◽  
Elsir Osman ◽  
Andrew K. Burroughs ◽  
James S. Owen
Keyword(s):  
Liver Disease ◽  
Oral Administration ◽  
Chronic Liver Disease ◽  
Therapeutic Potential ◽  
Plasma Cholesterol ◽  
Chronic Liver ◽  
Erythrocyte Membranes ◽  
Molar Ratio ◽  
Mean Values ◽  
The Mean

1. S-Adenosyl-l-methionine is reported to improve serum liver function tests in chronic liver disease. Because liver disease is complicated by cholesterol deposition in hepatic and extrahepatic membranes, we have assessed whether oral administration of S-adenosyl-l-methionine to patients with hepatic disease can reverse the cholesterol enrichment of their erythrocytes. 2. The mean erythrocyte cholesterol-to-phospholipid molar ratio in 13 jaundiced patients was reduced 2 weeks after oral administration of S-adenosyl-l-methionine (from 0.874 ± 0.112 to 0.844 ± 0.102, P<0.05) with 10 of the patients (77%) showing a decrease. By contrast, only four of 11 untreated patients (36%) had a reduced erythrocyte cholesterol-to-phospholipid molar ratio after 2 weeks and the mean values did not differ. 3. The plasma and erythrocyte cholesterol-to-phospholipid molar ratios remained closely correlated (r = 0.77, P<0.01) before and after treatment, suggesting that S-adenosyl-l-methionine had not acted directly on the cells but rather had improved their lipoprotein milieu. Further support for this concept was provided by following one patient, who initially failed to respond, during an additional 3 weeks of S-adenosyl-l-methionine administration. The plasma cholesterol-to-phospholipid molar ratio fell steadily from week 1 to week 5 and was accompanied by a progressive decrease in the erythrocyte cholesterol-to-phospholipid molar ratio. Moreover, the initially suppressed acetylcholinesterase activity of the erythrocyte membranes returned towards normal during this period. 4. This preliminary study is the first evidence in jaundiced patients that a drug can help to reverse the deposition of cholesterol in an extrahepatic membrane. It merits, therefore, placebo-controlled, crossover investigations into the therapeutic potential of S-adenosyl-l-methionine in chronic liver disease.

Insulin Resistance and Hyperinsulinemia in Patients with Chronic Liver Disease and Hepatocellular Carcinoma

2009 ◽  
Vol 2 ◽  
pp. CMED.S3116 ◽  
Author(s):  
Valter Donadon ◽  
Massimiliano Balbi ◽  
Antonio Perciaccante ◽  
Pietro Casarin ◽  
Giorgio Zanette
Keyword(s):  
Hepatocellular Carcinoma ◽  
Insulin Resistance ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Healthy Subjects ◽  
Chronic Liver ◽  
Metabolic Factors ◽  
Mean Values ◽  
The Mean

Objectives To investigate the role of insulin resistance (IR) and insulin plasma levels (IRI) in patients with chronic liver disease (CLD) and hepatocellular carcinoma (HCC). Methods We recruited the following patients: 125 with HCC, 128 with liver cirrhosis (LC) and 133 with chronic hepatitis C (CHC). IR was assessed by the HOMA-IR method. To define IR and hyperinsulinemia we selected as a cut-off level, the value of the 80th percentile for HOMA-IR (2.72) and IRI (11.18) in 113 healthy subjects. Results The mean levels of HOMA-IR and IRI increase progressively among CHC (2.7 ± 2.9 and 11.5 ± 10.5, respectively), LC (5.4 ± 4.5 and 17.6 ± 11.2) and HCC (6.4 ± 9.8 and 18.2 ± 18.8). In the upper quintiles for HOMA-IR and IRI, the frequency of patients in the LC and HCC groups was twice as much in CHC cases. HCC with DM2 have the greatest percentage above the 80th percentile of HOMA-IR, their quintiles distribution is inverted and HOMA-IR mean values are significantly higher in comparison with HCC without DM2 cases. Discussion Our study shows that the association between IR and CLD begins in the early stages of liver fibrosis. DM2 increases HOMA-IR and IRI mean levels in HCC patients and these metabolic factors could play a major role in the link between diabetes mellitus and hepatocarcinoma.

scholarly journals TOLAK UKUR FUNGSI HATI BERDASARKAN DERAJAT FIBROSIS PENYAKIT HATI KRONIS (Liver Function Parameters based on Degree of Liver Fibrosis in Chronic Liver Disease)

2018 ◽  
Vol 21 (1) ◽  
pp. 57
Author(s):  
Rahmafitria Rahmafitria ◽  
Mutmainnah Mutmainnah ◽  
Ibrahim Abdul Samad
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Total Bilirubin ◽  
Chronic Liver ◽  
Low Degree ◽  
Significant Difference ◽  
The Mean ◽  
High Degree

Evaluating the degree of liver fibrosis degree is invasive as well as uncomfortable, therefore, non invasive examinations such as liverfunction tests and elastography (Fibro Scan) as a predictor‘s device of liver fibrosis degree are necessary. The aim of this study was toknow the differences of liver function parameters based on the fibrosis degree in patients with chronic liver disease. This study was a crosssectional design using data from chronic liver disease patients treated at the Dr. Wahidin Sudirohusodo Hospital. The elasticity of the liverwas measured using a fibro scan device during June 2010–July 2011. The analysis was carried out by ANOVA test on various parametersof liver function particularly on the fibrosis degree in chronic liver disease. In this study PT, albumin, total bilirubin and platelet countshowed a significant difference of 0.019, 0.009, 0.017 and 0.000 respectively. The mean values of PT and total bilirubin were significantlyhigher in the high degree of fibrosis compared to those with medium and low degree of fibrosis in the chronic liver disease patients. Basedon this study, the mean albumin levels and platelet count were significantly lower in the high degree of fibrosis compared with the mediumand low degree of fibrosis, however, no significant differences in AST, ALT, APTT and GGT were found.

Immature Platelet Fraction in Patients with Chronic Liver Disease, A Marker for Evaluating Cirrhotic Changes.

2021 ◽  
Vol 17 (2) ◽  
pp. 174-179
Author(s):  
Muhammad Javaid Iqbal ◽  
Muhammad Usman ◽  
Mubarak Ali Anjum ◽  
Yasir Yaqoob ◽  
Ghulam Mujtaba Nasir ◽  
...  
Keyword(s):  
Platelet Count ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
White Blood Cells ◽  
Chronic Liver ◽  
Control Group ◽  
P Value ◽  
Master Program ◽  
Immature Platelet Fraction ◽  
The Mean

Objective: To evaluate the role of Immature platelet fraction in patients with chronic liver disease, a marker for evaluating cirrhotic changes. Methodology: This case control study was conducted at department of Pathology, Aziz Fatima Medical and Dental College, Faisalabad, over a period of Seven months from June 2020 to January 2021. A total of 126 participants were included in the study consisting of 63 patients with chronic liver disease in group A and 63 participants without any known disease in group B as control. The IPF master program in combination with XE-2100 multiparameter automatic hematology analyzer was used to measure the immature platelet fraction. Ethylene diamine tetraacetic acid was used to collect the blood sample for IPF measurement and was maintained till analysis on room temperature. Ten repeated analyses, immediately and after 24 hours were done for reproducibility of IPF%. Results: The mean age of liver disease patients was 52.35 ± 13.64 years and in control group the mean age was 51.62 ± 11.27 years. There was no significant (p-value > 0.05) difference between both groups based on age and gender. The hemoglobin level and red cell count was found to be significantly (p-value < 0.05) reduced in cases group. While white blood cells count was comparable in both groups. The mean platelet count was significantly (p-value < 0.05) less in cases group (163.5 ± 90.4 vs 233.4 ± 54.5 (x10*3/µl). The mean value of immature platelet fraction (IPF%) was significantly (p-value < 0.05) raised in cases group (5.62 ± 2.92 vs 3.06 ± 1.87). The multivariate discriminant analysis (MDA) score showed a significant (p-value < 0.05) association with chronic hepatis as compared to other liver related diseases. Conclusions: In chronic liver disease patients, there is an inverse relationship between platelet count and IPF% with decreased platelet count and increased IPF%. The proposed MDA function can be used to identify the cirrhotic changes in liver disease patients.

scholarly journals Colonoscopic band ligation for internal hemorrhoids - A tertiary care experience

2013 ◽  
Vol 04 (01) ◽  
pp. 006-009 ◽  
Author(s):  
Umesh Jalihal ◽  
Satya Prakash B S. ◽  
Avinash B. ◽  
Dheeraj Karanth
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Tertiary Care ◽  
Rubber Band Ligation ◽  
Rubber Band ◽  
Chronic Liver ◽  
Band Ligation ◽  
Care Experience ◽  
Internal Hemorrhoids ◽  
The Mean

ABSTRACT Background and objectives: Rubber band ligation (BL) is the most widely used technique for treatment of symptomatic internal haemorrhoids (IH) that are refractory to conservative treatment. The aim of this study is to assess the efficacy of colonoscopic BL as therapy for symptomatic IH. Methods: Patients seen at our center with symptomatic IH who underwent BL between January 2006 and December 2011 were included in this prospective study. The clinical and colonoscopic details were entered in uniform structured data forms. Results: Two hundred and eighteen consecutive patients with symptomatic IH were enrolled in the study. The presentations were rectal bleeding in 150 (69%) and prolapse in remaining 68 (31%) patients. Twenty-four patients (11%) had chronic liver disease (child B-C). Same operator treated all the patients. The severity of the IH was classified by using Goligher grading system. The mean age of patients was 48.3 + 15 years with range of 22 - 85 years. The mean follow up was 3months (range 1 month - 36 months). In 209 patients (96%) there was at least 1 grade reduction in hemorrhoids as well the symptoms were controlled. Two patients required surgery and another 7 patients required repeat session of banding. After banding session 32 (15%) patients had perianal pain and 13 (6%) had mild bleeding. Conclusions: Colonoscopic BL is a safe, and effective outpatient therapeutic procedure for symptomatic internal hemorrhoids. Furthermore, the BL is safe and effective in patients of coagulopathy associated with chronic liver disease. (J Dig Endosc 2013;4(1):6–9)

Quality of Life Score in Patients with Chronic Liver Disease using CLO Questionnaire

2021 ◽  
Vol 15 (11) ◽  
pp. 3467-3469
Author(s):  
Niaz Muhammad ◽  
Kashif Rafi ◽  
Hassan Nadeem ◽  
Muhammad Omer Farooq ◽  
Asmat Ullah ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Life Score ◽  
Class B ◽  
Pugh Class ◽  
The Mean ◽  
Class C

Aim: To determine the quality of life score in patients with chronic liver disease using CLO questionnaire. Study Design: Cross sectional study Place and Duration: Department of Gastroenterology, Shaikh Zayed Hospital Lahore during from 14-June-2016to 15-December-2016. Methodology: 180 consecutive patients of chronic liver disease were selected after taking Informed consent. The diagnosis was confirmed according to the data of clinical, biochemical examinations and the results of percutaneous liver biopsy data in some selected cases. All patients were subjected to exam, LFT's, RFT's and CBC, ultrasound abdomen, esophagogastroscopy which were enrolled in this study. Anti HCV, HBsAg, ferritin, Cerruloplasmin and Autoimmune profile, was done to establish the etiology. Severity of liver disease was estimated by Child-Pugh Score (Annexed). The chronic liver disease questionnaire (CLDQ) was applied as the instrument for measuring quality of life. Results: The mean age of the patients was 35.28±7.26 years. Majority of the patients were male as there frequency was 142 (78.9%). 127 (70.60 %) cases were found to be having a child pugh grade c severity of disease. Mean quality of life score was 16.3±5.88. Mean quality of life score in males was 16.21±6.21 while in female was 16.63±4.48. Similarly the mean quality of life score in child pugh class B was 13.77±4.58 and in child pugh class C was 17.35±6.05. Conclusion: It is concluded that the quality of life was bad in the patients who had child pugh class C as compared to those who had class B. Keywords: Quality of Life, Chronic Liver Disease, Cirrhosis

scholarly journals Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania

2005 ◽  
Vol 134 (1) ◽  
pp. 95-101 ◽  
Author(s):  
L. A. KONDILI ◽  
P. CHIONNE ◽  
A. PORCARO ◽  
E. MADONNA ◽  
S. TAFFON ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Case Control Study ◽  
Age Groups ◽  
Hepatitis E ◽  
Case Control ◽  
Chronic Liver ◽  
The Mean ◽  
End Stage ◽  
Control Study

SUMMARYA case-control study involving 109 in-patients with chronic liver disease and 190 in-patients with no apparent liver disease was conducted to evaluate the seroprevalence of anti-HEV antibodies and the possible association with chronic liver disease. Among cases, the anti-HEV prevalence was 36·6% which increased significantly by age; among controls, the prevalence was 12·1% (P<0·05) and was similar among age groups <60 years. Among cases, aged >50 years (OR 4·0, 95% CI 1·4–11) and the presence of end stage liver disease (ESLD) (OR 4·3, 95% CI 1·4–12·8) were associated independently with anti-HEV positivity. The mean optical density, determined by anti-HEV immunoenzymatic test, was significantly higher among patients with ESLD, compared to the other patients. These results indicate that there is a high seroprevalence of anti-HEV in patients with chronic liver disease and a possible association between HEV infection and/or anti-HEV production and advanced stage chronic liver disease.

Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease.

1984 ◽  
Vol 30 (2) ◽  
pp. 211-215 ◽  
Author(s):  
I Myara ◽  
A Myara ◽  
M Mangeot ◽  
M Fabre ◽  
C Charpentier ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Total Bilirubin ◽  
Early Stage ◽  
Chronic Liver ◽  
Easy Method ◽  
Prolidase Activity ◽  
Ccl4 Administration ◽  
The Mean

Abstract We describe here an easy method of determining prolidase (EC 3.4.13.9) in plasma after preincubation with Mn2+ for 24 h at 37 degrees C to maximize prolidase activity. The mean activity in 338 patients who were either in hospital or outpatients was 900 U/L +/- 520 (2 SD), unrelated to sex or age. In 25 of these 338 samples tested, prolidase activity was between 1500 and 2000 U/L. It exceeded 2000 U/L in eight, all of whom were patients with chronic liver disease. Plasma prolidase activity was normal in cytolytic syndromes such as liver or heart disease. Of the 27 patients with cirrhosis, only five exhibited prolidase activity greater than 2000 U/L. Plasma prolidase activity was uncorrelated with six biochemical indexes to liver function (the aminotransferases, alkaline phosphatase, glutamyltransferase, total bilirubin, and serum albumin) or with the degree of cirrhotic fibrosis. We believe that plasma prolidase activity may be high only in the early stage of fibrosis. This hypothesis would be consistent with the data on rat-liver collagenolytic activities during CCl4 administration. Monitoring of plasma prolidase activity might be useful in evaluating fibrotic processes in chronic liver disease in the human.

Association of serum glycated albumin to haemoglobin A1C ratio with hepatic function tests in patients with chronic liver disease

2009 ◽  
Vol 46 (5) ◽  
pp. 368-372 ◽  
Author(s):  
Yukihiro Bando ◽  
Hideo Kanehara ◽  
Daisyu Toya ◽  
Nobuyoshi Tanaka ◽  
Soji Kasayama ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Plasma Glucose ◽  
Glycated Albumin ◽  
Hepatic Function ◽  
Chronic Liver ◽  
Diabetic Patients ◽  
Haemoglobin A1c ◽  
Glucose Levels ◽  
The Mean

Background In patients with chronic liver disease (CLD), glycated haemoglobin (HbA1C) levels have been shown to be apparently lower than real values, whereas serum glycated albumin (GA) levels are apparently higher. The present study was aimed to examine whether both glycaemic indices are influenced by hepatic function. Methods Subjects consisted of 82 patients with CLD. Various indicators for hepatic function as well as HbA1C and GA were also measured. Estimated HbA1C values were calculated from the mean plasma glucose levels. Two hundred and two type 2 diabetic patients without CLD were studied as controls. Results Although GA was strongly correlated with HbA1C in patients with CLD as well as diabetic patients, GA levels in patients with CLD were relatively higher than those in diabetic patients. In patients with estimated HbA1C ≤5.8%, GA levels significantly increased but HbA1C levels decreased as a function of decreasing hepaplastin test (HPT). The ratio of GA/HbA1C (G/H ratio) increased as a function of decreasing HPT. In patients with estimated HbA1C >5.8%, in contrast, GA levels were independent of HPT levels. In the patients with CLD, GA and HbA1C were associated with mean plasma glucose levels and some indicators for hepatic function. The multivariate analysis revealed a significant association of G/H ratio with HPT, cholinesterase and direct bilirubin. The G/H ratio was not associated with the mean plasma glucose but with HPT and cholinesterase levels. Conclusions The G/H ratio correlates with hepatic function but not with plasma glucose levels. Therefore, CLD should be suspected for diabetic patients with an elevated G/H ratio.

Sign in / Sign up

Export Citation Format

Share Document